Sanofi Under EU Probe Over Flu Vaccine

European regulators are probing Sanofi over alleged anti-competitive tactics in promoting its flu vaccine, Efluelda, in France and Germany—accusations that the company may have unfairly attacked a rival’s product, Fluad. With Sanofi dominating the market in those countries, authorities are scrutinizing whether the company abused its position. Sanofi denies wrongdoing, insists it’s cooperating fully, and maintains compliance with all laws. The investigation began after surprise inspections in September 2025, signaling serious concerns. Watch this space—big pharma isn’t immune to regulatory scrutiny. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/9182ff9e13758340